

22 Dec 2022 | Analysis

Chinese-Language Podcast: 中国 mRNA 疫苗

by Brian Yang

After China eased its "COVID Zero" policies, infections have surged in Beijing, Guangzhou and other cities, likely prompting the National Health Security Administration to delay the closely-watched annual drug reimbursement pricing negotiations. Meanwhile, Pfizer has signed a new distribution deal with state-owned Meheco to meet surging demand for its oral antiviral Paxlovid in the country, while at least two domestically developed mRNA vaccines are now awaiting approval. Also, Chinese biotechs are looking at three main methods of surviving and thriving.

“[中国 mRNA 疫苗](#)” (Also see "[Pharma Execs Urge 'Balance' In China Payer Price Negotiations](#)" - Scrip, 6 Dec, 2022.)

[Paxlovid](#) [nirmatrevir](#) [ritonavir](#) [MEHECO](#) [Paxlovid](#) 2022年12月18日 [Paxlovid](#)

[mRNA](#) [mRNA](#) (Also see "[Drugs In Short Supply As China Hunkers Down For COVID Surge](#)" - Scrip, 15 Dec, 2022.)

[Harbour BioMed](#) CEO [divestment](#) (Also see "[Podcast: Biotech CEO Interview – Harbour BioMed's Wang On Moderna Deal, New Subsidiary](#)" - Scrip, 18 Nov, 2022.)

[中国 mRNA 疫苗](#)



[Click here to explore this interactive content online](#) 